Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida from March 11-13, 2025.
The company's founder, chairman and CEO Robert Wessman, along with management team members, will conduct one-on-one meetings during the event. Additionally, Alvotech will participate in a fireside chat on March 12, 2025, from 9:30-9:55 am EDT. The session will be available via audio webcast in the Events Section of Alvotech's Investor Portal, with the recording accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), un'azienda biotech globale focalizzata sullo sviluppo di medicinali biosimilari, ha annunciato la sua partecipazione alla 27ª Conferenza Sanitaria Globale Annuale Barclays che si terrà a Miami, Florida, dal 11 al 13 marzo 2025.
Il fondatore, presidente e CEO dell'azienda, Robert Wessman, insieme ai membri del team di gestione, condurrà incontri individuali durante l'evento. Inoltre, Alvotech parteciperà a una chiacchierata informale il 12 marzo 2025, dalle 9:30 alle 9:55 EDT. La sessione sarà disponibile tramite audio webcast nella Sezione Eventi del Portale Investitori di Alvotech, con la registrazione accessibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en el desarrollo de medicamentos biosimilares, ha anunciado su participación en la 27ª Conferencia Anual Global de Salud de Barclays en Miami, Florida, del 11 al 13 de marzo de 2025.
El fundador, presidente y CEO de la empresa, Robert Wessman, junto con miembros del equipo de gestión, llevará a cabo reuniones uno a uno durante el evento. Además, Alvotech participará en una charla informal el 12 de marzo de 2025, de 9:30 a 9:55 a.m. EDT. La sesión estará disponible a través de un webcast de audio en la Sección de Eventos del Portal de Inversores de Alvotech, con la grabación accesible durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 중점을 둔 글로벌 생명공학 회사로, 2025년 3월 11일부터 13일까지 플로리다주 마이애미에서 열리는 바클레이스 제27회 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다.
회사의 창립자이자 회장 및 CEO인 로버트 웨스만과 경영진이 행사 기간 동안 일대일 미팅을 진행할 예정입니다. 또한, Alvotech는 2025년 3월 12일 오전 9시 30분부터 9시 55분(EDT)까지 진행되는 파이어사이드 채팅에도 참여합니다. 이 세션은 Alvotech의 투자자 포털 이벤트 섹션에서 오디오 웹캐스트를 통해 제공되며, 이벤트 종료 후 90일 동안 녹음이 접근 가능합니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale axée sur le développement de médicaments biosimilaires, a annoncé sa participation à la 27e Conférence Annuelle Mondiale sur la Santé de Barclays qui se tiendra à Miami, Floride, du 11 au 13 mars 2025.
Le fondateur, président et PDG de l'entreprise, Robert Wessman, ainsi que des membres de l'équipe de direction, mèneront des réunions individuelles pendant l'événement. De plus, Alvotech participera à une discussion informelle le 12 mars 2025, de 9h30 à 9h55 EDT. La session sera disponible via un webinaire audio dans la section Événements du Portail Investisseurs d'Alvotech, avec l'enregistrement accessible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung von biosimilaren Arzneimitteln konzentriert, hat seine Teilnahme an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami, Florida, vom 11. bis 13. März 2025 angekündigt.
Der Gründer, Vorsitzende und CEO des Unternehmens, Robert Wessman, wird zusammen mit Mitgliedern des Managementteams während der Veranstaltung Einzelgespräche führen. Darüber hinaus wird Alvotech am 12. März 2025 von 9:30 bis 9:55 Uhr EDT an einem Fireside-Chat teilnehmen. Die Sitzung wird über einen Audio-Webcast im Bereich Veranstaltungen des Investorenportals von Alvotech verfügbar sein, mit einer Aufzeichnung, die 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fireside chat on Wednesday, March 12, 2025, at 9:30-9:55 am EDT (13:30-13:55 GMT).
An audio webcast of the fireside chat will also be available to investors and the general public and can be accessed in the Events Section of Alvotech’s Investor Portal. After the event, a recording will also be available for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When is Alvotech (ALVO) presenting at the Barclays Healthcare Conference 2025?
How can investors access Alvotech's (ALVO) presentation at the Barclays Conference?
Who will represent Alvotech (ALVO) at the Barclays Healthcare Conference 2025?
What type of investor interactions will Alvotech (ALVO) have at the Barclays Conference?
